An ongoing phase III trial in postmenopausal women carrying BRCA1/2 mutations is underway to investigate breast cancer incidence and recurrence with letrozole therapy (LIBER trial; NCT00673335). The gene discussed is BRCA1; the disease is breast carcinoma.